{"id":"capecitabine-plus-temozolamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is a fluoropyrimidine carbamate that is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. Temozolamide is an alkylating agent that methylates DNA at the O6 position of guanine, causing DNA strand breaks and apoptosis. The combination leverages different mechanisms of cytotoxicity to enhance anti-tumor activity.","oneSentence":"Capecitabine and temozolamide are chemotherapy agents that work together to inhibit DNA synthesis and induce cell death in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:55.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme (Phase 3 trial)"},{"name":"Brain tumors"}]},"trialDetails":[{"nctId":"NCT07185672","phase":"PHASE3","title":"PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2019-08-07","conditions":"Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAPE-TEM"],"phase":"phase_3","status":"active","brandName":"Capecitabine plus temozolamide","genericName":"Capecitabine plus temozolamide","companyName":"Tata Memorial Hospital","companyId":"tata-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine and temozolamide are chemotherapy agents that work together to inhibit DNA synthesis and induce cell death in cancer cells. Used for Glioblastoma multiforme (Phase 3 trial), Brain tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}